Abstract
The ADAT2/ADAT3 complex catalyzes the adenosine to inosine modification at the wobble position of eukaryotic tRNAs. Mutations in ADAT3, the catalytically inactive subunit of the ADAT2/ADAT3 complex, have been identified in patients presenting with severe neurodevelopmental disorders (NDDs). Yet, the physiological function of ADAT2/ADAT3 complex during brain development remains totally unknown. Here we showed that maintaining a proper level of ADAT2/ADAT3 catalytic activity is required for correct radial migration of projection neurons in the developing mouse cortex. In addition, we not only reported 7 new NDD patients carrying biallelic variants in ADAT3 but also deeply characterize the impact of those variants on ADAT2/ADAT3 structure, biochemical properties, enzymatic activity and tRNAs editing and abundance. We demonstrated that all the identified variants alter both the expression and the activity of the complex leading to a significant decrease of I34 with direct consequence on their steady-state. Using in vivo complementation assays, we correlated the severity of the migration phenotype with the degree of the loss of function caused by the variants. Altogether, our results indicate a critical role of ADAT2/ADAT3 during cortical development and provide cellular and molecular insights into the pathogenicity of ADAT3-related neurodevelopmental disorder.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from INSERM (ATIP-Avenir program, J.D.G.), the French state funds through the Agence Nationale de la Recherche (ANR-21-CE12-0026 to J.D.G., C.R. and L.D.; ANR-DFG ANR-19-CE16-0023 to J.D.G. and D.D.N.; ANR-10-IDEX-0002-02 and ANR-10-LABX-0030-INRT to J.D.G. and C.R.), ERC CoG 2021 TransNeuroFate (J.G.), SFRI-STRAT′US project [ANR 20-SFRI-0012]; and EUR IMCBio [ANR-17-EURE-0023]), INSERM/CNRS (J.D.G., C.R, and L.D.) and University of Strasbourg (J.D.G., C.R., and L.D.). D.D.N. is funded by the Max Planck Society, the European Research Council under the European Union′s Horizon 2020 Research and Innovation Programme (ERC Starting Grant 803825-TransTempoFold) and the EMBO Young Investigator Program (YIP 4833). E.B. was supported by INSERM, Fondation Jerome Lejeune and ANR. R.L. is supported by Ministère de l'Enseignement Supérieur de la Recherche et de l'Innovation. E.Br is supported by Fondation pour la recherche médicale. P.T. is research assistant at the University of Strasbourg. C.R. is a CNRS investigator. J.D.G. is an INSERM investigator. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Patient 5, 6, 7) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. CAW is supported by a grant from the NINDS (RO1 NS35129) and is an Investigator of the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Inclusion and genetic studies were approved by the ethics committee of the Broad Institute of MIT, Boston, USA, of Cairo University Faculty of Medicine Research, Boston Children's Hospital, the University of California, San Diego, USA and the Cambridge University Hospital, Cambridge, UK. All participants or their legal representatives gave their consent to take part in the present study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data produced in the present study are available upon reasonable request to the corresponding authors.
